An antioxidant-free compound amino acid injection, its preparation method and application
By employing a segmented feeding strategy of pre-dissolving cysteine, methionine, and tryptophan in acetic acid and using nitrogen protection, the stability problem of easily oxidized amino acids in compound amino acid injections has been solved, achieving high stability and safety. This approach is suitable for various patient groups and industrial production.
Patent Information
- Application Number
- CN202611181819.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-05
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2046-08-05
AI Technical Summary
Existing compound amino acid injections, without the addition of antioxidants, are unable to effectively protect the stability of easily oxidized amino acids such as cysteine, methionine, and tryptophan during production, sterilization, and storage. In particular, the sulfhydryl groups of cysteine are easily oxidized, leading to reduced efficacy and increased levels of related substances. At the same time, exogenous antioxidants pose safety risks.
The method of pre-dissolving cysteine in acetic acid is adopted. Under nitrogen protection, cysteine is dissolved in 40-80% acetic acid solution to create a local low pH environment and block the oxidation reaction. Methionine is added in an independent stage to consume the oxidation load. Tryptophan is added in the final stage to provide light shielding. Combined with nitrogen protection and gradient filtration, the entire process is stabilized.
It achieves ultra-long-term stability of compound amino acid injection under conditions without exogenous antioxidants, with high cysteine retention rate and low total related substances, avoiding the safety hazards of exogenous antioxidants, suitable for a variety of patient groups, and the process is simple and suitable for industrial production.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of compound amino acid injection technology, and specifically to a method for preparing a compound amino acid injection without antioxidants. Background Technology
[0002] Compound amino acid injections are an important component of parenteral nutrition support, providing the body with amino acid substrates and are widely used for patients who cannot take oral medication or require enhanced nutrition. Among them, the compound amino acid injection containing 17 amino acids (17AA-Ⅲ specification) is one of the commonly used clinical varieties. Its formula includes arginine, tyrosine, isoleucine, leucine, lysine acetate, phenylalanine, threonine, valine, alanine, aspartic acid, proline, serine, histidine, glycine, methionine, tryptophan, and cysteine.
[0003] Of the 17 amino acids, cysteine, methionine, and tryptophan are easily oxidized, especially cysteine. The thiol group (-SH) in the cysteine molecule has a pKa of approximately 8.3. Under neutral to alkaline conditions, the thiol group exists as a sulfhydryl anion (-S...). - It exists in the form of ) and has high chemical reactivity. It is easily catalytically oxidized by dissolved oxygen and metal ions to form disulfide bonds (forming cystine dimers), leading to reduced drug efficacy and increased levels of related substances. The thioether group of methionine can also be oxidized to methionine sulfoxide; the indole ring of tryptophan is easily photo-oxidized and degraded under light conditions.
[0004] Currently marketed compound amino acid injections containing cysteine (such as Lvganan®) typically add sodium bisulfite (0.25g / L) as an antioxidant to inhibit the oxidative degradation of sulfur-containing amino acids. However, sulfite antioxidants themselves pose safety risks: some patients experience allergic reactions, which can lead to adverse reactions such as difficulty breathing and decreased blood pressure in severe cases; sulfites can decompose into sulfates during sterilization and storage, increasing the total amount of related substances in the solution; furthermore, the presence of sulfites can interfere with the determination of the content of some amino acids. Therefore, developing compound amino acid injections without sulfite antioxidants has become an industry consensus.
[0005] After sulfite removal, ensuring the stability of easily oxidized amino acids, especially cysteine, during production, sterilization, and storage through appropriate process methods has become a technical challenge. Existing technologies have proposed several strategies to address this issue: Chinese patent application CN202110219955 discloses a sulfite-free compound amino acid injection solution, which uses a buffer system composed of malic acid and citric acid / sodium citrate to replace sulfite. This solution achieves antioxidant protection by adjusting the overall pH of the solution, but essentially provides indiscriminate passive protection for all 17 amino acids. Because different amino acids have significantly different oxidation mechanisms and sensitivities—cysteine thiol groups are sensitive to dissolved oxygen, methionine thioether groups are sensitive to oxidative load, and tryptophan indole rings are sensitive to light—the indiscriminate overall buffering strategy cannot provide precise protection against the oxidation mechanisms of specific amino acids, especially offering limited protection for cysteine, which has the highest oxidation sensitivity.
[0006] Chinese patent CN116251058B discloses a method for preparing an antioxidant-free cystine-containing amino acid injection, in which cystine is pre-dissolved in hydrochloric acid solution before being added to the main drug solution. Cystine and cysteine differ fundamentally in molecular structure, oxidation behavior, and pharmacodynamic properties. Cystine (C6H...) 12 N2O4S2 is a dimer formed by two cysteine molecules coupled through disulfide bonds (-SS-). It lacks free thiol groups (-SH) and its disulfide bonds are already in their highest oxidation state, making it chemically stable and preventing thiol oxidation in solution. Therefore, cysteine predissolution only requires strong acid to break intermolecular hydrogen bonds, a physical problem of "how to dissolve." Its solubility at room temperature is less than 0.2 g / L, and direct addition cannot achieve the prescribed concentration; therefore, a strong acid environment is necessary to promote dissolution. However, the solubility problem and the oxidation stability problem are fundamentally different in technical nature. The hydrochloric acid predissolution scheme in Chinese patent CN116251058B addresses the "dissolution" problem, with its technical endpoint being complete dissolution of cysteine, without considering post-dissolution molecular environmental protection. The challenge for cysteine, however, is preventing oxidation after dissolution; once the protective solution is added to the main drug solution, the local pH rises, and the thiol groups rapidly deprotonate to -S. - The oxidation reaction then begins. Furthermore, hydrochloric acid, as a strong monocarboxylic acid, introduces a large amount of chloride ions during the pre-dissolution process. The residual chloride ions in the injection solution not only increase the osmotic pressure burden but may also catalyze the oxidative degradation of sulfur-containing amino acids through ionic effects.
[0007] Cystine is formed by the oxidation of two cysteine molecules through a disulfide bond (-SS-), and lacks a free sulfhydryl group. After entering the cell, it must be reduced by a reducing equivalent (NADPH, vitamin C) to break down into two cysteine molecules to exert its function. In healthy adults, the body's reducing capacity is sufficient, and cystine can be slowly converted. However, in premature infants, newborns, patients with severe trauma, liver and kidney failure, or those suffering from severe oxidative stress, the body's reducing system is insufficient, hindering cysteine reduction and preventing the adequate production of active cysteine. This leads to insufficient glutathione synthesis, decreased antioxidant capacity, and exacerbated liver damage. Specifically, amino acid preparations for newborns must include cysteine hydrochloride and not cystine.
[0008] Chinese patent application CN202511886259 discloses a method for preparing an amino acid injection solution, employing a protective gas-sealed container and a specific feeding sequence, placing cysteine in the last feeding stage and using acetic acid as a pH adjuster. Although this method adjusts the feeding sequence and adds cysteine last, during feeding, cysteine is directly added to the main drug solution in the form of solid powder or ordinary aqueous solution. This means that the sulfhydryl groups of cysteine are exposed to the slightly acidic drug solution environment the moment it is added, lacking molecular-level pre-protection and unable to effectively cope with the oxidative load during feeding and mixing.
[0009] Chinese patent application CN202511623701 discloses a grouped feeding scheme using acetylcysteine to replace sulfite, in which the amino acids are divided into three groups and fed separately. Acetylcysteine and free cysteine differ fundamentally in molecular structure, oxidation behavior, and pharmacodynamic properties: the thiol group of acetylcysteine is blocked by an acetyl group, and its oxidation sensitivity and reactivity are completely different from those of free thiol groups. Therefore, the feeding strategy and stabilization scheme based on acetylcysteine cannot be directly applied to injection systems using free cysteine as the active ingredient.
[0010] Chinese patent application CN115317590A discloses a sulfite-free amino acid injection solution that uses acetylcysteine combined with nitrogen protection and closed-loop feeding for stabilization. This approach also relies on acetylcysteine derivatives and depends solely on physical oxygen-barrier methods such as nitrogen protection and closed-loop operation, without designing a targeted chemical protection strategy based on the inherent chemical properties of the amino acids. Under conditions of high dissolved oxygen concentrations or unavoidable trace oxygen infiltration, the lack of a chemical protection mechanism will lead to the gradual oxidative degradation of sulfur-containing amino acids.
[0011] Furthermore, while using acetylcysteine derivatives instead of free cysteine offers advantages, although acetylcysteine has a higher pKa (approximately 9.5) and lower oxidative sensitivity in solution compared to free cysteine, thus reducing reliance on antioxidants, acetylcysteine is not a standard component of amino acid injections. Its α-amino group is blocked by an acetyl group, preventing direct use in protein synthesis. It requires hepatic deacetylation to convert to free cysteine before utilization. This metabolic process is limited by liver enzyme activity and produces acetate byproducts, posing an additional metabolic burden for the primary target population of amino acid injections, such as patients with hepatic impairment. Additionally, intravenous administration of acetylcysteine has a higher incidence of allergic reactions, making repeated long-term parenteral nutrition administration significantly more risky than using free cysteine.
[0012] Therefore, there is an urgent need in this field to develop a method for preparing compound amino acid injections that can achieve synergistic protection of multiple easily oxidized amino acids by using targeted feeding strategies and process design without adding any antioxidants, and by fully combining the chemical characteristics and intermolecular interactions of each amino acid. Summary of the Invention
[0013] The present invention aims to overcome at least one of the defects of the prior art and provide a compound amino acid injection without antioxidants, its preparation method and application, so as to achieve the purpose of high stability and high safety of the prepared compound amino acid injection.
[0014] Specifically, this invention provides a method for preparing a compound amino acid injection without antioxidants, comprising the following steps: S1. Dissolve the prescribed amount of cysteine in an acetic acid solution with a mass-volume percentage of 40-80% prepared under nitrogen protection to prepare a cysteine protective solution with a cysteine concentration of 0.5-2.0 g / L. S2. Add a predetermined amount of water for injection to the mixing tank, and fill the mixing tank with nitrogen until the dissolved oxygen is stable at no more than 0.2 ppm to obtain the basic solvent; S3. Arginine, tyrosine, isoleucine, leucine, lysine acetate, phenylalanine, threonine, valine, alanine, aspartic acid, proline, serine, histidine, and glycine are added to the base solvent and stirred continuously until all solid materials are completely clear and dissolved to obtain the initial drug solution. S4. Add methionine to the initial drug solution, stir to dissolve, then add tryptophan and continue stirring to obtain the first mixed drug solution. S5. The cysteine acetic acid protective solution is added dropwise to the first mixed drug solution at a rate of 1L / min to 2.5L / min, while stirring during the addition process, and the mixture is stirred to obtain the second mixed drug solution. S6. Add water for injection to dilute the second mixed drug solution to a final volume. Under nitrogen protection, reflux and circulate the drug solution for 20 minutes to obtain the final drug solution. Step S1 is completed at any stage prior to step S5.
[0015] Preferably, in step S1, the acetic acid solution has a mass-volume percentage of 60%.
[0016] The most crucial fundamental innovation of this invention lies in the acetic acid pre-dissolution operation in step S1. The pKa of cysteine thiol (-SH) is approximately 8.3. Within the target pH range (6.6~7.6) of the compound amino acid injection, according to the Henderson-Hasselbalch equation, approximately 90%~95% of the thiol groups are in a protonated (-SH) state, with only about 5%~10% being deprotonated sulfide anions (-S). - (Form). However, -S - Its nucleophilicity is much higher than that of -SH, and the thiol radical (RS•) generated by its oxidation by dissolved oxygen can further catalyze the oxidation of adjacent -SH, forming a chain reaction. Therefore, even trace amounts of -S - This is also sufficient to trigger irreversible oxidative degradation of cysteine. This invention uses a 40%–80% (w / v) acetic acid solution to pre-dissolve cysteine. Utilizing the weakly acidic dissociation equilibrium of acetic acid (pKa = 4.76), a locally low pH (approximately pH 2.0–3.5) microenvironment is created at the moment of dissolution, ensuring the stable existence of cysteine sulfhydryl groups in a fully protonated (-SH) form, thus blocking the initiation of the oxidation reaction at its source. This protective effect is maintained throughout the storage phase of the protective solution until it is slowly added dropwise to the main drug solution, where the locally acidic environment is diluted by a large amount of the drug solution. During this process, the thiol-protonated state of cysteine gradually deprotonates as the pH rises. However, since cysteine is already fully dispersed in the drug solution during the dropwise addition, the collision frequency between thiol groups and dissolved oxygen is limited by both the dilution effect and the low-oxygen environment, resulting in a significant reduction in the oxidation reaction rate. Simultaneously, after the cysteine protective solution is added to the main drug solution, it is rapidly and uniformly dispersed in a large amount of drug solution under thorough stirring, avoiding the oxidation risk of localized high-concentration cysteine areas. Furthermore, at this point, the dissolved oxygen in the drug solution has been reduced to ≤0.2 ppm after nitrogen deoxygenation, and the low-oxygen environment further reduces the substrate concentration for thiol oxidation. This two-stage mechanism of "acidic pre-protection during dissolution—low-oxygen dilution protection after dispersion" achieves full-chain thiol stabilization from the feed source to the final formulation.
[0017] The thioether group (-S-CH3) of methionine has a moderate redox potential and can preferentially undergo a mild oxidation reaction with dissolved oxygen under normal temperature liquid phase conditions to generate methionine sulfoxide. In this invention, methionine is added independently in the S4 stage, allowing it to be fully contacted with residual dissolved oxygen in the final solution beforehand. The thioether group actively consumes the initial oxidative load in the system, creating a low-oxidative-pressure chemical environment for the subsequent addition of cysteine.
[0018] The timing of methionine addition has a decisive impact on its protective effect. If methionine and cysteine are added simultaneously, while the thioether groups consume dissolved oxygen, the adjacent thiol groups still face the attack of locally unremoved dissolved oxygen. Furthermore, the two substances compete for residual dissolved oxygen in the system during dissolution, leading to a decrease in the oxygen removal efficiency of methionine and an increase in the oxidation risk of cysteine. Only timely addition in stage S4 ensures that methionine completes its oxygen removal mission before the addition of cysteine, providing continuous and long-term protection during subsequent storage.
[0019] The indole ring of tryptophan exhibits strong ultraviolet absorption around 280 nm, with a molar extinction coefficient of 5.6 × 10³ M. - ¹·cm - ¹, Under the feeding sequence of this invention, tryptophan exists in a uniformly dispersed state in the final drug solution. Its indole ring can preferentially absorb ultraviolet light energy, reducing its own photo-oxidative degradation risk. At the same time, the reduction of tryptophan photodegradation products also indirectly reduces its catalytic oxidation risk to methionine and cysteine. In this invention, tryptophan is added in the S4 stage (after methionine dissolves), so that it is distributed in a uniform molecular dispersion state in the final drug solution, ensuring that the light shielding effect covers the entire drug solution system.
[0020] The timing of ingredient addition has a decisive impact on the light-shielding effect: if tryptophan is added simultaneously with the other 14 amino acids in stage S3, the indole ring may accumulate due to local supersaturation during subsequent incubation, stirring, and the addition of cysteine protective solution, leading to a decrease in light absorption efficiency and loss of light-shielding uniformity. If tryptophan and cysteine are added together to the acetic acid protective solution, a nucleophilic addition side reaction of thiol-indole may occur in the acidic environment, resulting in mutual consumption. If the amount of tryptophan is low, the absolute concentration of indole rings is insufficient, failing to form an effective light-shielding molecular layer. If the amount is too high, excess tryptophan will produce more photodegradation products due to intermolecular self-sensitization photo-oxidation. Therefore, only by adding tryptophan in stage S4, within the optimal concentration range explored in this invention, can tryptophan function as a highly efficient endogenous light-shielding agent in a uniformly dispersed molecular state.
[0021] Furthermore, step S5 also includes adjusting the pH of the second mixed solution, specifically by adjusting the pH value to 6.6~7.6 using glacial acetic acid solution.
[0022] More preferably, the present invention further includes a step of multi-stage filtration of the final drug solution: S7. Primary filtration is performed using composite PES filter elements of 0.65μm and 0.45μm. S8. Secondary filtration is performed using a 0.22μm PES sterilization filter cartridge; S9. Three-stage filtration is performed using a 0.22μm PES terminal sterilization filter cartridge to obtain the filtered drug solution. The pressure of the multi-stage filtration is maintained at 0.10 MPa to 0.30 MPa.
[0023] More preferably, the temperature of the final drug solution is maintained at 20°C to 40°C during the secondary and tertiary filtration processes.
[0024] More preferably, the preparation method of the compound amino acid injection of the present invention further includes a filling and sterilization step: S10. Filling: Fill the filtered medicine solution into glass infusion bottles, and accurately control the headspace residual oxygen content in the bottle to ≤1.0% after filling; S11. Sterilization: Sterilization temperature 121.0℃, sterilization time 12min, after sterilization, cooling in stages to obtain compound amino acid injection.
[0025] Furthermore, in steps S2, S3, S4, and S5, the water temperature for injection is controlled to be constant at 65±5℃.
[0026] This invention also protects the application of the above-described preparation method in the preparation of amino acid-based intravenous nutrition drugs.
[0027] The present invention also protects a compound amino acid injection solution obtained based on the above preparation method, comprising arginine, tyrosine, isoleucine, leucine, lysine acetate, phenylalanine, threonine, valine, alanine, aspartic acid, proline, serine, histidine, glycine, methionine, tryptophan, cysteine, and water for injection.
[0028] Specifically, the concentrations are as follows: arginine (13.93 g / L to 16.91 g / L); tyrosine (0.36 g / L to 0.44 g / L); isoleucine (8.28 g / L to 10.12 g / L); leucine (8.51 g / L to 10.40 g / L); lysine acetate (3.56 g / L to 4.35 g / L); phenylalanine (0.27 g / L to 0.33 g / L); threonine (1.93 g / L to 2.35 g / L); valine (8.01 g / L to 9.79 g / L); and alanine (...). The concentrations of the following amino acids were: 7.56 g / L to 9.24 g / L; aspartic acid concentration: 0.18 g / L to 0.22 g / L; proline concentration: 4.77 g / L to 5.83 g / L; serine concentration: 2.34 g / L to 2.86 g / L; histidine concentration: 2.79 g / L to 3.41 g / L; glycine concentration: 4.86 g / L to 5.94 g / L; methionine concentration: 0.40 g / L to 0.48 g / L; tryptophan concentration: 0.63 g / L to 0.77 g / L; and cysteine concentration: 0.23 g / L to 0.28 g / L.
[0029] Compared with the prior art, the beneficial effects of the present invention are as follows: (i) Achieving ultra-long-term stability under antioxidant-free conditions This invention constructs a four-fold synergistic protection network: acetic acid pre-dissolution to lock in thiol-methionine, pre-consuming the oxidative load, and tryptophan optimization for photostability; segmented feeding; full-process physical oxygen isolation; gradient filtration; and time-limited sterilization. This achieves comprehensive stability of the compound amino acid injection without adding any exogenous antioxidants. Accelerated stability tests (6 months) and long-term stability tests (12 months at 25°C) show that the cysteine retention rate in the examples remains above 86%, total related substances are below 0.50%, and the solution remains colorless and clear. In photostability tests, the tryptophan retention rate in the examples is ≥90%, while most comparative examples are below the 85% threshold. This indicates that this invention, without adding any antioxidants, comprehensively outperforms existing sulfite-containing solutions in terms of stability, solving the industry's long-standing technical bottleneck of relying on exogenous antioxidants.
[0030] (ii) Completely eliminate the safety hazards caused by exogenous antioxidants This invention completely eliminates the need for exogenous antioxidants such as sodium bisulfite and acetylcysteine, thus removing the risk of sulfites inducing allergic reactions in some patients, especially asthma patients. It also avoids the adverse effects of secondary impurities such as sulfates and sulfides produced by the continuous decomposition of sulfites during sterilization and storage on the quality of the drug solution. Compared to alternatives using acetylcysteine derivatives, this invention directly uses free cysteine as the active ingredient, eliminating the need for hepatic deacetylation, making it suitable for patients with hepatic impairment, and further reducing the risk of allergic reactions when administered intravenously. Furthermore, this invention uses acetic acid instead of hydrochloric acid to pre-dissolve cysteine, preventing the introduction of additional chloride ions into the final drug solution and avoiding interference with osmotic pressure and amino acid stability caused by residual chloride ions.
[0031] (iii) The process is simple, widely applicable, and suitable for industrial production. The raw materials used in this invention are 17 common amino acids, requiring no special derivatives or salts; the equipment used is standard pharmaceutical production equipment, requiring no complex modifications; each operation step is a mature pharmaceutical unit process, which can be directly promoted and applied to existing compound amino acid injection production lines. Furthermore, the preparation method of this invention has successfully achieved industrial-scale production at a capacity of 4000L, with product quality highly consistent with the small-scale test, demonstrating that this invention has good scalability and batch-to-batch consistency, and possesses significant industrial application value. Detailed Implementation
[0032] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described below with reference to specific embodiments, but the scope of protection of this invention is not limited thereto. Experimental methods in the embodiments that do not specify specific conditions are generally performed under conventional conditions or according to the manufacturer's recommendations. Unless otherwise specified, all reagents and materials used are commercially available.
[0033] Example 1 A method for preparing an antioxidant-free compound amino acid injection includes the following steps: S1. Preparation of cysteine protective solution: Under nitrogen protection (oxygen content < 0.5%), dissolve 0.25 g / L cysteine in 60% (w / v) acetic acid solution and stir thoroughly until completely clear and dissolved to obtain cysteine acetic acid protective solution.
[0034] S2. Preparation of the basic solvent: Add approximately 800 mL of water for injection to a 1000 mL mixing tank, and purge the tank with high-purity nitrogen until the dissolved oxygen (DO) stabilizes at no more than 0.2 ppm to obtain the basic solvent. The water temperature is controlled at 65±5℃.
[0035] S3. Preparation of the initial drug solution: Arginine 15.42g, tyrosine 0.40g, isoleucine 9.20g, leucine 9.46g, lysine acetate 3.96g, phenylalanine 0.30g, threonine 2.14g, valine 8.90g, alanine 8.40g, aspartic acid 0.20g, proline 5.30g, serine 2.60g, histidine 3.10g, and glycine 5.40g were added sequentially to the base solvent. The mixture was stirred continuously until all solids were completely dissolved and clear, yielding the initial drug solution. The water temperature was controlled at 65±5℃.
[0036] S4. Preparation of the first mixed solution: First, add 0.44g of methionine to the initial solution and stir to dissolve. Then, add 0.70g of tryptophan and continue stirring to ensure that the methionine and tryptophan are fully mixed to obtain the first mixed solution.
[0037] S5. Preparation of the second mixed solution: The cysteine acetic acid protective solution obtained in step S1 is slowly added dropwise to the first mixed solution (dropping rate is about 1~2.5L / min). After the addition is complete, the solution is mixed well and the pH value is adjusted to 6.6~7.6 with glacial acetic acid solution to obtain the second mixed solution. The pH value of the solution is 7.1, which is within the standard range and does not need to be adjusted.
[0038] S6. Preparation of final drug solution: Dilute to 1000 mL with water for injection, and under nitrogen protection, reflux and circulate the drug solution for 20 min to obtain the final drug solution.
[0039] S7. Primary filtration: Pre-filtration is performed using composite PES filter elements of 0.65μm and 0.45μm, with the filtration pressure maintained at 0.10~0.30MPa.
[0040] S8. Secondary filtration: Sterilization filtration is performed using a 0.22μm PES sterilization filter element. The temperature of the solution is maintained at 20~40℃ and the filtration pressure is maintained at 0.10~0.30MPa.
[0041] S9. Three-stage filtration: Terminal filtration is performed using a 0.22μm PES terminal sterilization filter cartridge. The temperature of the drug solution is maintained at 20~40℃, and the filtration pressure is maintained at 0.10~0.30MPa to obtain the filtered drug solution.
[0042] S10. Filling: Fill the filtered medicine solution into glass infusion bottles, and accurately control the headspace residual oxygen content in the bottle to ≤1.0% after filling.
[0043] S11. Sterilization: The filled infusion bottles are sent into a sterilization cabinet at a sterilization temperature of 121.0℃ for 12 minutes. After sterilization, the bottles are cooled to room temperature in stages to obtain the compound amino acid injection product.
[0044] Example 2 Experimental objective: To verify the protective effect of acetic acid concentration at the lower limit of 40% on cysteine.
[0045] The only difference between this embodiment and Embodiment 1 is that in step S1, a 40% (w / v) acetic acid solution is used. The remaining steps and parameters are the same as in Embodiment 1.
[0046] Example 3 Experimental objective: To verify the protective effect of acetic acid concentration at the upper limit of 80% on cysteine.
[0047] The only difference between this embodiment and Embodiment 1 is that in step S1, an 80% (w / v) acetic acid solution is used. The remaining steps and parameters are the same as in Embodiment 1.
[0048] Example 4 Experimental objective: To verify the stability of the product when the pH is adjusted to the lower limit of 6.6.
[0049] The only difference between this embodiment and Embodiment 1 is that in step S5, the pH value is adjusted to 6.6 using glacial acetic acid solution. All other steps and parameters are the same as in Embodiment 1.
[0050] Example 5 Experimental objective: To verify the stability of the product when the pH is adjusted to the upper limit of 7.6.
[0051] The only difference between this embodiment and Embodiment 1 is that in step S5, the pH value is adjusted to 7.6 using glacial acetic acid solution. The remaining steps and parameters are the same as in Embodiment 1.
[0052] Example 6 Experimental objective: To verify the effect of water temperature for injection (60±5℃) on amino acid dissolution efficiency and product stability.
[0053] The only difference between this embodiment and Embodiment 1 is that the water temperature for injection is controlled at 60±5℃ in steps S2, S3, S4, and S5. The remaining steps and parameters are the same as in Embodiment 1.
[0054] Example 7 Experimental objective: To verify the effect of water temperature for injection (70±5℃) on amino acid dissolution efficiency and product stability.
[0055] The only difference between this embodiment and Embodiment 1 is that the water temperature for injection is controlled at 70±5℃ in steps S2, S3, S4, and S5. The remaining steps and parameters are the same as in Embodiment 1.
[0056] Example 8 Experimental objective: To verify the stability and safety of the product when the sterilization time is extended to 15 minutes.
[0057] The only difference between this embodiment and Embodiment 1 is that in step S11, the sterilization time is 15 minutes. The remaining steps and parameters are the same as in Embodiment 1.
[0058] Example 9 Experimental objective: To investigate the stability and safety of products prepared with different concentrations of added amino acids.
[0059] The preparation method in this embodiment is the same as that in Example 1, except that the amount of amino acids added in this embodiment is as shown in the table below: Table 1. Amino acid formulation composition of Example 9
[0060] Example 10 Experimental objective: To investigate the stability and safety of products prepared with different concentrations of added amino acids.
[0061] The difference between this embodiment and Example 1 is that the amount of amino acids added in this embodiment is shown in the table below: Table 2. Amino acid formulation composition of Example 10
[0062] Example 11 This embodiment is a scale-up preparation experiment of the method of the present invention, namely the industrial preparation of 17 kinds of amino acid injection solution in 4000L specification.
[0063] S1. Using a 5L wide-mouth bottle, take 3kg of glacial acetic acid each time and dilute it with water for injection to 5L. Keep the bottle under nitrogen protection throughout the process. Repeat the operation until 20.16kg of glacial acetic acid is consumed to prepare a sufficient amount of 60% (W / V) acetic acid solution. Add the prescribed amount of cysteine and stir until completely dissolved to obtain a cysteine protective solution. Seal the bottle and keep it under nitrogen for later use.
[0064] S2. Preparation of basic solvent: Add 3600 kg of water for injection to the mixing tank and control the temperature at 65°C; introduce high-purity nitrogen gas and stir at 60 Hz until the dissolved oxygen drops to 0.18 ppm; S3. Add 14 amino acids in sequence: arginine, tyrosine, isoleucine, leucine, lysine acetate, phenylalanine, threonine, valine, alanine, aspartic acid, proline, serine, histidine, and glycine, and stir until completely dissolved to obtain the initial drug solution. S4. Add methionine to the initial drug solution, stir to dissolve, then add tryptophan and continue stirring to obtain the first mixed drug solution. S5. Slowly add cysteine acetate protective solution, spray the container wall with water for injection, and stir for 15 minutes; the pH value of the solution is 7.1, which is within the standard range and does not require adjustment.
[0065] S6. Volumetric circulation: Add water for injection to bring the volume to 4000L, then reflux with nitrogen for 20 minutes.
[0066] S7~S9, graded filtration: sequentially filtered through a 0.65+0.45μm primary filter element and two 0.22μm PES filter elements, with the filtration temperature controlled at 30℃ and the filtration pressure controlled at 0.25MPa.
[0067] S10~S11, Filling and Sterilization: Fill into 500ml glass infusion bottles, control headspace residual oxygen level to 0.8%; sterilize at 121℃ for 12min, cool, inspect by light, and package to obtain the finished injection solution.
[0068] Comparative Example 1 Experimental objective: To verify the stability of cysteine under conditions without acetic acid pre-dissolution protection.
[0069] The difference between this comparative example and Example 1 is that: the cysteine acetic acid protective solution is not prepared; instead, the prescribed amount of cysteine is added to the basic solvent along with 16 other amino acids: arginine, tyrosine, isoleucine, leucine, lysine acetate, phenylalanine, threonine, valine, alanine, aspartic acid, proline, serine, histidine, glycine, methionine, and tryptophan, and stirred continuously until completely clear and dissolved. The protective solution addition operation in steps S1 and S5 is omitted; the pH value is adjusted to 7.1 using glacial acetic acid solution in step S5 is retained, and the remaining steps are the same.
[0070] Comparative Example 2 Experimental objective: To verify the protective effect of thiol groups when cysteine is dissolved in neutral water.
[0071] The difference between this comparative example and Example 1 is that in step S1, cysteine is dissolved in water for injection to obtain an aqueous cysteine solution. In step S5, this aqueous solution is slowly added dropwise to the first mixed drug solution. The remaining steps and parameters are the same as in Example 1.
[0072] Comparative Example 3 Experimental objective: To verify the difference in the effects of hydrochloric acid pre-dissolving cysteine and acetic acid pre-dissolving cysteine, in accordance with CN116251058B.
[0073] The difference between this comparative example and Example 1 is that in step S1, cysteine is dissolved in a 1 mol / L hydrochloric acid solution to obtain a cysteine hydrochloric acid protective solution. In step S5, this hydrochloric acid protective solution is slowly added dropwise to the first mixed drug solution. The remaining steps and parameters are the same as in Example 1.
[0074] Comparative Example 4 Experimental objective: To verify the effectiveness of using moderately strong acid phosphate as a substitute for weak acid acetic acid in predissolving cysteine.
[0075] The difference between this comparative example and Example 1 is that in step S1, cysteine is dissolved in a 1 mol / L phosphoric acid solution to obtain a cysteine phosphate protective solution. In step S5, this phosphate protective solution is slowly added dropwise to the first mixed drug solution. The remaining steps and parameters are the same as in Example 1.
[0076] Comparative Example 5 Experimental objective: To verify the effect of citric acid, a tribasic acid, on predissolving cysteine in the example of using acetic acid, a monobasic acid.
[0077] The difference between this comparative example and Example 1 is that in step S1, cysteine is dissolved in a 60% (w / v) citric acid solution to obtain a cysteine citric acid protective solution. In step S5, this citric acid protective solution is slowly added dropwise to the first mixed drug solution. The remaining steps and parameters are the same as in Example 1.
[0078] Comparative Example 6 Experimental objective: To verify the stability of cysteine when it is directly added as a solid powder.
[0079] The difference between this comparative example and Example 1 is that: no cysteine protective solution is prepared; instead, cysteine is added directly to the first mixed solution in solid powder form. The protective solution addition operation in steps S1 and S5 is omitted; the step of adjusting the pH to 7.1 using glacial acetic acid solution in step S5 is retained, and the remaining steps are the same.
[0080] Comparative Example 7 Experimental objective: To serve as a positive control, benchmarking against commercially available regimens containing sulfite antioxidants.
[0081] The difference between this comparative example and Example 1 is as follows: Based on the formulation of Example 1, an additional 0.25 g / L of sodium bisulfite was added as an antioxidant; the cysteine acetic acid protective solution was not prepared; instead, the prescribed amount of cysteine and the other 16 amino acids were added to the base solvent and stirred continuously until completely clear and dissolved. The protective solution addition operation in steps S1 and S5 was omitted; the pH value was adjusted to 7.1 using glacial acetic acid solution in step S5 was retained; the remaining process parameters were the same as in Example 1.
[0082] Comparative examples 8-13 were used to explore the effect of different acetic acid concentrations on the stability of cysteine.
[0083] Comparative Example 8 The difference between this comparative example and Example 1 is that in step S1, the mass-volume percentage of the acetic acid solution is 20%. The remaining steps and parameters are the same as in Example 1.
[0084] Comparative Example 9 The difference between this comparative example and Example 1 is that in step S1, the mass-volume percentage of the acetic acid solution is 30%. The remaining steps and parameters are the same as in Example 1.
[0085] Comparative Example 10 The difference between this comparative example and Example 1 is that in step S1, the mass-volume percentage of the acetic acid solution is 35%. The remaining steps and parameters are the same as in Example 1.
[0086] Comparative Example 11 The difference between this comparative example and Example 1 is that in step S1, the mass-volume percentage of the acetic acid solution is 38%. The remaining steps and parameters are the same as in Example 1.
[0087] Comparative Example 12 The difference between this comparative example and Example 1 is that in step S1, the mass-volume percentage of the acetic acid solution is 85%. The remaining steps and parameters are the same as in Example 1.
[0088] Comparative Example 13 The difference between this comparative example and Example 1 is that in step S1, the mass-volume percentage of the acetic acid solution is 90%. The remaining steps and parameters are the same as in Example 1.
[0089] Comparative Examples 14-19 were used to investigate the effect of the methionine-tryptophan feeding order on product stability. Comparative Example 14 Experimental objective: To verify the effect of simultaneous administration of methionine and tryptophan.
[0090] The difference between this comparative example and Example 1 is that in step S4, the prescribed amounts of methionine and tryptophan are simultaneously added to the initial drug solution and stirred to obtain the first mixed drug solution. The remaining steps and parameters are the same as in Example 1.
[0091] Comparative Example 15 Experimental objective: To verify the effect of reverse feeding order, i.e., tryptophan first and then methionine.
[0092] The difference between this comparative example and Example 1 is that in step S4, the prescribed amount of tryptophan is first added to the initial drug solution, stirred and dissolved, and then methionine is added and stirred and mixed to obtain the first mixed drug solution. The remaining steps and parameters are the same as in Example 1.
[0093] Comparative Example 16 Experimental objective: To verify the effect of methionine and tryptophan being fed simultaneously with 14 other amino acids without an independent feeding stage.
[0094] The difference between this comparative example and Example 1 is that in step S3, the prescribed amounts of methionine, tryptophan, and 14 stable amino acids—arginine, tyrosine, isoleucine, leucine, lysine acetate, phenylalanine, threonine, valine, alanine, aspartic acid, proline, serine, histidine, and glycine—are added to the base solvent. The separate step S4 is omitted; the remaining steps are the same.
[0095] Comparative Example 17 Experimental objective: To verify the effect of adding methionine, tryptophan, and cysteine to the acetic acid protective solution at the end.
[0096] The difference between this comparative example and Example 1 is that in step S3, only 14 stable amino acids (excluding methionine, tryptophan, and cysteine) are added to the base solvent. The prescribed amounts of methionine, tryptophan, and cysteine are dissolved together in a 60% (w / v) acetic acid solution to prepare a mixed protective solution. In step S5, this mixed protective solution is slowly added dropwise to the initial drug solution. The remaining steps and parameters are the same as in Example 1.
[0097] Comparative Example 18 Experimental objective: To verify the effect of adding tryptophan first and then adding only methionine in the middle stage.
[0098] The difference between this comparative example and Example 1 is that in step S3, tryptophan is added to the base solvent along with 14 stable amino acids. In step S4, only methionine is added separately. The remaining steps and parameters are the same as in Example 1.
[0099] Comparative Example 19 Experimental objective: To verify the effect of adding methionine first and adding tryptophan alone in the middle stage.
[0100] The difference between this comparative example and Example 1 is that in step S3, methionine is added to the base solvent along with 14 stable amino acids. In step S4, only tryptophan is added alone. The remaining steps and parameters are the same as in Example 1.
[0101] Comparative examples 20-22 were used to investigate the effect of methionine addition on product stability.
[0102] Comparative Example 20 Experimental objective: To verify the stability of cysteine when methionine and cysteine are added to a protective solution simultaneously.
[0103] The difference between this comparative example and Example 1 is as follows: In step S3, 15 amino acids (excluding methionine and cysteine) are added to the base solvent. In step S1, methionine and cysteine are dissolved together in a 60% (w / v) acetic acid solution to obtain a mixed protective solution. In step S5, this mixed protective solution is slowly added dropwise to the initial drug solution. The separate step S4 is omitted. The remaining steps and parameters are the same as in Example 1.
[0104] Comparative Example 21 Experimental objective: To verify that when methionine is dissolved in water for injection in the S2 stage, the time interval between its dissolution and the addition of cysteine is the longest, and to investigate its protective effect on cysteine.
[0105] The difference between this comparative example and Example 1 is as follows: In step S2, after nitrogen purging and deoxygenation, methionine is directly dissolved in water for injection, a basic solvent containing methionine, to obtain a basic solvent. In step S3, 14 stable amino acids are added to this methionine-containing basic solvent. In step S4, tryptophan is added and stirred until homogeneous. The remaining steps and parameters are the same as in Example 1.
[0106] Comparative Example 22 Experimental objective: To replace methionine with an equal amount of glycine.
[0107] The difference between this comparative example and Example 1 is that glycine is used instead of methionine in equal amounts. In step S3, 15 amino acids (including additional glycine to replace methionine, but excluding cysteine) are added to the base solvent. The separate step S4 is omitted; in step S4, only tryptophan is added. The remaining steps and parameters are the same as in Example 1.
[0108] Comparative Examples 23-26 investigated the effect of tryptophan addition on product stability. Comparative Example 23 Experimental objective: To verify the photoprotective effect of tryptophan when dissolved in water for injection during the S2 stage.
[0109] The difference between this comparative example and Example 1 is as follows: In step S2, after nitrogen purging and deoxygenation, tryptophan is directly dissolved in water for injection, a basic solvent containing tryptophan. In step S3, 14 stable amino acids (excluding methionine, tryptophan, and cysteine) are added to this tryptophan-containing basic solvent. In step S4, only methionine is added and stirred to dissolve. The remaining steps and parameters are the same as in Example 1.
[0110] Comparative Example 24 Experimental objective: To verify the photoprotective effect of tryptophan in acetic acid protective solution.
[0111] The difference between this comparative example and Example 1 is as follows: In step S3, 15 amino acids (excluding tryptophan and cysteine) are added to the base solvent. In step S1, tryptophan and cysteine are dissolved together in a 60% (w / v) acetic acid solution to obtain a mixed protective solution. In step S5, this mixed protective solution is slowly added dropwise to the first mixed drug solution. The remaining steps and parameters are the same as in Example 1.
[0112] Comparative Example 25 Experimental objective: To investigate the dose-response effect of tryptophan photoprotection.
[0113] The difference between this comparative example and Example 1 is that the amount of tryptophan used was reduced from 0.70 g / L to 0.55 g / L. The remaining steps and parameters are the same as in Example 1.
[0114] Comparative Example 26 Experimental objective: To investigate the upper limit of photoprotection of high-concentration tryptophan and the impact of excessive tryptophan on product safety.
[0115] The difference between this comparative example and Example 1 is that the amount of tryptophan used was increased from 0.70 g / L to 0.85 g / L. The remaining steps and parameters are the same as in Example 1.
[0116] Comparative Examples 27-32 investigated the process parameters of the compound amino acid injection of the present invention. Comparative Example 27 Experimental objective: To verify the stability of the product without nitrogen deoxygenation.
[0117] The difference between this comparative example and Example 1 is that in step S2, nitrogen is not introduced into the mixing tank, and dissolved oxygen is not controlled. The remaining steps and parameters are the same as in Example 1.
[0118] Comparative Example 28 Experimental objective: To verify the stability of the product when dissolved oxygen control is relaxed to 0.3 ppm.
[0119] The difference between this comparative example and Example 1 is that in step S2, nitrogen gas is introduced into the mixing tank until the dissolved oxygen level is stable at no more than 0.3 ppm (replacing 0.2 ppm). The remaining steps and parameters are the same as in Example 1.
[0120] Comparative Example 29 Experimental objective: To verify the stability of the product during long-term storage when the headspace residual oxygen is relaxed to 1.5%.
[0121] The difference between this comparative example and Example 1 is that in step S10, the residual oxygen content in the headspace of the bottle is controlled to be ≤1.5% after filling. The remaining steps and parameters are the same as in Example 1.
[0122] Comparative Example 30 Experimental objective: To verify the impact of two-stage filtration on the control of insoluble particulate matter and product stability.
[0123] The difference between this comparative example and Example 1 is that step S7 (first-stage filtration) is omitted, and only two-stage filtration is performed: step S8 (0.22μm PES sterilization filter cartridge) and step S9 (0.22μm PES terminal sterilization filter cartridge). The remaining steps and parameters are the same as in Example 1.
[0124] Comparative Example 31 Experimental objective: To verify the impact of two-stage filtration on the control of insoluble particulate matter and product stability.
[0125] The difference between this comparative example and Example 1 is that step S8 is omitted, and only steps S7 and S9 are performed for two-stage filtering. The remaining steps and parameters are the same as in Example 1.
[0126] Comparative Example 32 Experimental objective: To verify the impact of two-stage filtration on the control of insoluble particulate matter and product stability.
[0127] The difference between this comparative example and Example 1 is that step S9 is omitted, and only steps S7 and S8 are performed for two-stage filtering. The remaining steps and parameters are the same as in Example 1.
[0128] Comparative Example 33 Experimental objective: To verify the effect of not performing reflux stirring on the uniformity of the drug solution and the stability of the product.
[0129] The difference between this comparative example and Example 1 is that in step S6, after adjusting the volume with water for injection, the reflux and stirring under nitrogen protection is not performed; instead, the mixture is allowed to stand. The remaining steps and parameters are the same as in Example 1.
[0130] Comparative Example 34 Experimental objective: To verify the effect of excessive heat load on the stability of cysteine and to demonstrate the rationality of the 12-minute sterilization time.
[0131] The difference between this comparative example and Example 1 is that in step S11, the sterilization temperature is 121.0℃ and the sterilization time is 18 minutes. The remaining steps and parameters are the same as in Example 1.
[0132] Detection indicators and experimental conditions The compound amino acid injections obtained in Examples 1-8 and Comparative Examples 1-34 were tested under the following conditions: I. Experimental Methods 1. Accelerated stability test According to the General Rules of Part IV of the 2025 Edition of the Chinese Pharmacopoeia <9001> The stability testing of active pharmaceutical ingredients (APIs) and pharmaceutical preparations was conducted in accordance with the guidelines. Samples were placed in a constant temperature and humidity chamber at 40℃±2℃ and 75%±5% relative humidity, and samples were taken for testing at 0, 1, 2, 3, and 6 months. The test indicators included: content of each amino acid (HPLC method), total related substances (HPLC method), cystine content, methionine sulfoxide content, pH value, insoluble particles, and appearance.
[0133] 2. Light stability test The light stability test shall be conducted according to the ICH Q1B guidelines. The sample shall be exposed to a total illuminance of not less than 1.2 × 10⁻⁶. 6 Under Lux·h illumination (including near-ultraviolet energy), samples were taken and tested at 0, 5, and 10 days. In addition to the accelerated testing, tryptophan retention rate and photodegradation products were added as detection indicators, with cysteine content measured at 0 days.
[0134] Among them, the calculation of cysteine retention rate Cysteine retention rate is calculated using the following formula: Retention rate (%) = C t / C0×100% In the formula: C0 represents the cysteine content in the sample at the initial time (month 0) (as a percentage of the labeled amount, %), determined by HPLC; C t The cysteine content (in percentage of labeled amount, %) in the sample after t months of storage was determined by HPLC in accelerated stability tests (40℃±2℃ / RH 75%±5%) or long-term stability tests (25℃).
[0135] HPLC determination conditions: Following the content determination method under "Compound Amino Acid Injection (17AA-Ⅲ)" in the 2025 edition of the Chinese Pharmacopoeia, Part II, an amino acid analyzer or high-performance liquid chromatography was used, employing ninhydrin post-column derivatization or 2,4-dinitrochlorobenzene pre-column derivatization. The content of each amino acid is expressed as a percentage (%) of the labeled amount.
[0136] 3. Judgment Criteria 4. • The content of each amino acid is ≥ 80% of the labeled amount; • The total amount of related substances ≤ 1.0%; • Cysteine retention rate ≥90%; • Tryptophan retention rate ≥85% (light test); • pH value: 6.6~7.6; • Insoluble particles: ≥10μm≤25 particles / mL, ≥25μm≤3 particles / mL; • Appearance: Colorless to slightly yellow clear liquid.
[0137] II. Experimental Results 1. Initial test results (0 months) The compound amino acid injection solutions obtained in Examples 1-11 and Comparative Examples 1-34 were subjected to full-item testing, and the results are shown in the table below. All samples met the release standards.
[0138] Table 3 Initial test results
[0139]
[0140] All samples met pharmacopoeia release standards immediately upon preparation, but the data already demonstrate the core advantages of this invention: the cysteine content and total related substances in all examples are generally superior to most comparative examples. At the principle level: This invention pre-prepares a 40-80% acetic acid-cysteine protective solution, utilizing the weakly acidic environment of acetic acid to lock the cysteine sulfhydryl groups into protonated -SH, thus pre-isolating oxidation before feeding; simultaneously, segmented feeding, nitrogen-controlled oxygen throughout the process (DO≤0.2ppm), and graded filtration work synergistically to reduce initial oxidation from both molecular chemical protection and physical oxygen isolation dimensions. In contrast, comparative examples either lacked acetic acid pre-protection, had incorrect acid system selection, disordered feeding sequence, or insufficient nitrogen deoxygenation, resulting in trace oxidation of cysteine during dissolution and feeding stages, leading to higher initial related substances and potential for later stability failure; while commercially available comparative example 7 containing sulfite had initial indicators close to the examples, it relied on exogenous antioxidants, resulting in safety defects such as allergies and increased impurities, lacking the technical advantages of pure process stabilization of this invention.
[0141] 2. Accelerated Stability Assessment - Month 1 Forty-six samples were subjected to accelerated testing at 40±2℃ / RH75±5% for one month, and samples were taken for testing.
[0142] Table 4. Results of accelerated testing after 1 month
[0143] Experimental conclusions After one month of acceleration, all examples 1-11 were qualified, with cysteine retention rate remaining above 98.0% and total related substances ≤0.22%, demonstrating excellent stability. In stark contrast, several comparative examples began to fail: (1) Comparative Example 1 (without acetic acid protection, cysteine and other amino acids were fed simultaneously) showed a sharp drop in cysteine retention rate to 82.0%, related substances rising to 0.85%, and methionine sulfoxide at 0.18%, exceeding the qualified standard. This directly proves the extreme instability of cysteine thiol groups in a neutral pH pharmaceutical environment: lacking the acidic microenvironment protection provided by acetic acid, the thiol groups rapidly deprotonate into highly active sulfur anions (-S).-The cysteine dimer impurities were continuously catalyzed and oxidized by trace amounts of dissolved oxygen in the system, and a large amount of cysteine dimer impurities were generated. At the same time, the oxidation of methionine sulfide groups was simultaneously aggravated to generate methionine sulfoxide. The double impurities exceeded the standard, resulting in the sample being unqualified. (2) Comparative Example 2 (cysteine dissolved in neutral water for injection) and Comparative Example 5 (preparation of protective solution with citric acid instead of acetic acid) were also unqualified, indicating that relying solely on nitrogen physical oxygen isolation is insufficient to completely inhibit thiol oxidation. Citric acid is a polybasic organic acid with a wide dissociation buffer system. It cannot construct a local low pH microenvironment at the moment of cysteine dissolution. It can only finely adjust the pH of the drug solution as a whole and cannot specifically lock the thiol protonation state. Compared with the mechanism of action of acetic acid monobasic weak acid instantaneous local acidification and precise shielding of thiol activity, there is an essential difference in the protective effect. (3) Comparative Example 6 (cysteine solid powder directly added to the main drug solution) had a cysteine retention rate of only 80.5% and related substances of 1.05%, which was the most serious unqualified. The solid cysteine dissolution process involves a solid-liquid interface. When a neutral drug solution is added, there is no acidic buffer barrier. The thiol groups at the interface are completely exposed to the dissolved oxygen oxidation load. The dissolution is accompanied by a violent oxidation reaction. The generated cysteine is irreversible and cannot be reversed by stirring or nitrogen replacement in the later stage. The degree of degradation is much higher than that of the pre-dissolution protection process. (4) In Comparative Example 27 (no nitrogen is used to control dissolved oxygen during the solution preparation stage), the cysteine retention rate dropped to 81.0%, and the related substances were 1.20%, which was also unqualified. This highlights the synergistic effect of the physical protection of low dissolved oxygen throughout the process of nitrogen and the chemical pre-protection of acetic acid. Acetic acid can only reduce the oxidation activity of thiol groups and cannot eliminate dissolved oxygen of the oxidizing substrate. When there is no nitrogen deoxygenation, the system continuously has a high concentration of oxygen, which will continuously consume protonated thiol groups and greatly weaken the protective effect of the acetic acid protective solution. (5) Comparative Example 11 (acetic acid concentration of 38%, which is lower than the 40% lower limit critical value of this invention) was judged to be critically qualified. The cysteine retention rate was 96.8% and the related substances were 0.35%, which were close to the unqualified threshold. The mechanism is that the acetic acid concentration is insufficient to completely maintain the protonation of all cysteine sulfhydryl groups, and some sulfhydryl groups still dissociate into sulfhydryl anions. Under long-term storage, oxidative degradation will continue to be amplified, proving that 40% is the minimum concentration threshold for the acetic acid protective solution to achieve effective molecular protection. (6) Comparative Example 7 (positive control with added sodium bisulfite antioxidant) showed a cysteine retention rate of 95.2% after 1 month, and the short-term antioxidant effect was acceptable, but its total related substances were 0.28%, which is slightly higher than all embodiments of the present invention (≤0.22%). Since sulfites themselves will slowly decompose under humid and hot accelerated conditions, generating secondary impurities such as sulfates and sulfides, and at the same time, sulfites can react with amino acids to continuously raise the level of total related substances, indicating that the long-term stability will continue to be inferior to the antioxidant-free process of the present invention.(7) The remaining comparative examples with deviations from a single process parameter (where the acetic acid concentration does not exceed the limit, the feeding sequence has a slight deviation, the filtration / sterilization parameters are slightly adjusted, etc.) are temporarily judged as qualified, but have a cysteine retention rate of 90.5~96.5% and related substances of 0.25~0.48%, and all overall indicators are comprehensively inferior to those of the example group. This proves that the complete set of process parameters of the present invention is a synergistically matched organic whole, and any deviation of process conditions from the optimal range will damage the multi-protection system of "acetic acid pre-protection - segmented feeding - low dissolved oxygen sealing", and accelerate the trace degradation of oxidizable amino acids.
[0144] 3. Accelerated stability test - Month 3 The samples that were qualified at the 1st month were continued for accelerated test until the 3rd month, and samples were taken for detection.
[0145] Table 5 Test results after 3 months of acceleration
[0146] Experiment summary: At the 3-month accelerated test point, all Examples 1 to 11 remain fully qualified, with the cysteine retention rate stably above 95.5%, the total related substances being only 0.30~0.38%, the degradation products increasing gently, and the long-term stability advantage being further enlarged. A large number of previously critically qualified comparative examples have become unqualified in batches, and the layered mechanism analysis is as follows: (1) Comparative Examples 8 to 10 (with acetic acid concentrations of 20% / 30% / 35%, significantly lower than the lower limit of 40%) are all unqualified, with the cysteine retention rate being only 84.0~88.0%. Low-concentration acetic acid cannot form a sufficient local acidic microenvironment, only a small amount of sulfhydryl groups are protonated, and the remaining free -S - continuously undergoes a chain oxidation reaction with trace oxygen in the system. As the acceleration time extends, the impurities of cystine and methionine sulfoxide continue to accumulate and exceed the qualification limit.
[0147] (2) Comparative Examples 12 and 13 (with acetic acid concentrations of 85% and 90%, higher than the upper limit of 80%) are unqualified. Excessive high-concentration acetic acid will change the overall buffer capacity of the medicinal solution, destroy the optimal stable pH range of 6.6~7.6 of the system, the acidic environment will indirectly catalyze the oxidation of the indole ring of tryptophan, and at the same time, the osmotic pressure disturbance brought by the excess acetic acid will intensify the side reactions between amino acid molecules, leading to a rapid increase in the total amount of impurities.
[0148] (3) Comparative Example 11 (with a critical acetic acid concentration of 38%) changed from critically qualified at Month 1 to unqualified at Month 3, which confirms that when the acetic acid concentration is lower than 40%, it can only delay oxidation in the short term, cannot inhibit the degradation of sulfhydryl groups for a long time, the oxidation products continue to accumulate under short-term accelerated conditions, and the protection for long-term storage fails.
[0149] (4) Comparative Examples 14-19 (methionine and tryptophan added in disordered order, simultaneous addition, and pre-addition) were batches that failed to meet standards. This indicates that the simultaneous addition of methionine and tryptophan to the initial solution in stage S4 of this invention is not only significant in terms of timing, but also in the synergistic and mutually protective effect of the two in the solution. Experimental results show that when methionine and tryptophan are added simultaneously in stage S4, the stability of the product is significantly better than when they are added separately or in disordered order (Comparative Examples 14-19). This phenomenon may be related to the fact that methionine pre-consumes the residual dissolved oxygen in the system and tryptophan exerts its light absorption effect in a uniformly dispersed state. The synergistic cooperation between the two in terms of timing achieves optimal protection for cysteine. The comparative example data of this application also show that when methionine and tryptophan are added separately or in disordered order, intermolecular association cannot be effectively established, and the cysteine retention rate drops to 87.5%-89.5% after 3 months, which is significantly lower than 96.8% in Example 1. Therefore, only by adding methionine and tryptophan simultaneously in the S4 stage can methionine preferentially consume residual dissolved oxygen before cysteine is added, and tryptophan exert its light absorption effect in a uniformly dispersed molecular state. The synergistic cooperation between the two in the time sequence achieves optimal protection against cysteine.
[0150] (5) Comparative Examples 20-22 (methionine and cysteine were added to the protective solution simultaneously, methionine was dissolved in the S2 stage in advance, and glycine was used to replace methionine) were all unqualified. Methionine is a natural oxygen scavenging auxiliary component in the system. Without methionine, there is no pathway for the active oxygen in the drug solution to be consumed, and it directly and continuously attacks the sulfhydryl groups of cysteine. Without multiple synergistic protection chains, oxidative degradation is significantly aggravated. In this invention, methionine is added independently in the S4 stage, so that it can fully contact the residual dissolved oxygen in the drug solution before the addition of cysteine. The thioether group preferentially undergoes two-electron oxidation (generating methionine sulfoxide), consuming the initial oxidative load in the system. This timing arrangement ensures that the oxidative pressure in the drug solution has been reduced to the minimum level when cysteine is added. The decisive influence of the feeding sequence on the protective effect of methionine can be further confirmed by Comparative Examples 20 and 21. If methionine and cysteine are added simultaneously (Comparative Example 20), they compete for residual dissolved oxygen during dissolution. Although the methionine thioether group preferentially reacts with dissolved oxygen, this reaction consumes oxygen, and any remaining dissolved oxygen that is not promptly removed can still oxidize the adjacent cysteine thiol group, leading to a decrease in the oxygen removal efficiency of methionine and an increase in the oxidation risk of cysteine. If methionine is dissolved in the base solvent in stage S2 (Comparative Example 21), the time interval between its addition and that of cysteine is too long. During the stirring process at 65°C, the thioether group undergoes slow oxidation and consumption due to continuous trace amounts of oxygen and thermodynamic effects, resulting in a significant decrease in protective activity by the time cysteine is added. Therefore, only timely addition in stage S4 ensures that methionine completes its oxygen removal mission before the addition of cysteine, while ensuring that sufficient residual methionine provides long-term protection after the addition of cysteine.
[0151] (6) Comparative Example 28 (dissolved oxygen in the solution was relaxed to 0.3 ppm, which is higher than the 0.2 ppm threshold of this invention) was deemed unqualified. Dissolved oxygen is the core substrate for amino acid oxidation. 0.3 ppm dissolved oxygen continuously provides oxidative raw materials. Acetic acid preprotection can only reduce the reaction rate and cannot isolate the oxygen substrate. Under long-term accelerated conditions, the oxidation of thiol groups can accumulate irreversibly.
[0152] (7) Although Comparative Example 7 (containing sulfite as a positive control) was still qualified, the cysteine retention rate was 93.5% and the related substances were 0.42%, which further widened the gap compared with the Example. Sulfite continued to decompose during storage, secondary impurities continued to increase, and sulfite would undergo addition side reactions with tryptophan and cysteine, continuously consuming active amino acids and accelerating the degradation rate.
[0153] (8) Although the remaining comparative samples with only slight deviations in filtration, sterilization, and headspace residual oxygen are temporarily qualified, the degradation index continues to rise and is very close to the unqualified threshold. Three-stage PES gradient filtration, filling headspace residual oxygen ≤1.0%, and 121℃×12min sterilization are all protective links of this invention. Relaxing the parameters of any link will introduce particulate matter, residual oxygen, and thermal damage, which will aggravate the oxidation of amino acids.
[0154] 4. Accelerated stability assessment – Month 6 The qualified samples from the third month were further accelerated and tested in the sixth month.
[0155] Table 6. Results of accelerated testing after 6 months
[0156] Experiment Summary: The six-month rigorous test endpoint was accelerated. Examples 1 to 11 all maintained the qualification, with cysteine retention rate ≥94.5% and total related substances only 0.48% at most, achieving long-term stability without any exogenous antioxidants. Except for Comparative Example 7 (with added sodium bisulfite), all other 35 comparative examples were judged to be unqualified. The analysis is as follows: (1) All comparative examples without acetic acid pre-protection, acetic acid concentration deviating from the 40~80% range, changing the acid system (hydrochloric acid / citric acid / phosphoric acid), and direct addition of solid cysteine were completely invalid. Since the construction of local low pH locking thiol matrix protonation by acetic acid pre-dissolution is the core basic innovation of this invention, other acidic systems do not have the instantaneous microenvironment regulation capability of acetic acid. Without the pre-protection process, cysteine will undergo irreversible oxidation from the feeding stage. Short-term acceleration only results in trace degradation, and after 6 months of long-term oxidation accumulation, impurities will exceed the standard. (2) All comparative examples with incorrect feeding sequence and missing methionine / tryptophan segmented feeding were unqualified. The segmented and step-by-step feeding process constructs a dual secondary protection of "methionine to remove active oxygen + tryptophan to resist photo-oxidation", forming a three-dimensional protection network with acetic acid chemical protection and nitrogen physical oxygen isolation; after the feeding sequence is disrupted, the secondary protection chain breaks, and acetic acid protection alone cannot resist the long-term oxygen and photo-oxidation load. (3) The process deviations of the comparative example, such as relaxed dissolved oxygen in the solution preparation, excessive residual oxygen in the headspace of the filling, reduction of the three-stage gradient filtration, and extension of sterilization time, are all unqualified. The whole process of low oxygen and airtight, gradient particle removal, and mild sterilization is a matching protection system. High residual oxygen, excessive insoluble particles, and excessive heat load will continue to catalyze the oxidation of sulfur-containing amino acids, and long-term storage will continue to amplify degradation. (4) Comparative Example 7 (sulfite antioxidant control) barely passed, with a cysteine retention rate of 91.2% and related substances of 0.62%, and all indicators were significantly worse than those of the example. Sulfites can only inhibit oxidation in the short term and cannot block the long-term synergistic degradation of heat, oxygen and light. Moreover, they continue to decompose to produce sulfate and sulfur-containing byproducts, and the total amount of impurities continues to rise. At the same time, sulfites pose a clinical allergy risk and cannot balance safety and stability. In contrast, the dual advantages of the antioxidant process of this invention are highlighted. (5) The S1 acetic acid pre-protection solution, S2 low dissolved oxygen base solvent, S3-S4 segmented differentiated feeding, S5 drop addition to control pH, S6 nitrogen circulation, three-stage PES gradient filtration, low residual oxygen filling, and limited moist heat sterilization parameters of this invention are an inseparable overall technical solution. A single technical feature cannot achieve long-term antioxidant effect. Existing technologies rely only on a single physical oxygen barrier or an overall buffer system, lacking precise layered protection for the three types of easily oxidized amino acids. Long-term storage will inevitably lead to degradation and failure.
[0157] 5. Results of photostability test The photostability of all 46 samples was investigated (under ICHQ1B conditions), and the results are shown in the table below.
[0158] Table 7 Results of the light stability test
[0159]
[0160] Light stability review (1) After the light test, all of Examples 1 to 11 were qualified, with tryptophan retention rate ≥90%, and methionine sulfoxide and total related substances were much lower than those of the various comparative examples, showing significant advantages in resisting photodegradation; most of the comparative examples were deemed unqualified because their tryptophan retention rate was less than 85%. The analysis is as follows: (1) All comparative examples without acetic acid preprotection and with direct addition of cysteine had extremely poor photostability, with tryptophan retention rate less than 80%. Mechanism: Cystine impurities generated by cysteine oxidation have photocatalytic effects, which will absorb light energy to accelerate the cracking of tryptophan indole ring. Without acetic acid protection, cysteine is oxidized in large quantities, and photosensitive impurities continue to accumulate, amplifying the photodegradation reaction. (2) All comparative examples with acetic acid concentration deviating from 40-80% and with citric acid / hydrochloric acid pre-dissolution were unqualified. Unsuitable acidic systems cannot stabilize cysteine, and photosensitive impurities continue to be generated in the system. At the same time, polybasic acids and strong acids will change the pH buffering characteristics of the drug solution, further reducing the photostability of tryptophan. (3) Comparative examples with disordered addition order of methionine and tryptophan showed severe photodegradation. In this invention, tryptophan is added in stage S4 (after methionine is dissolved) so that it exists in a uniform molecular dispersion state in the final drug solution. If tryptophan is added in stage S3 along with the other 14 amino acids (Comparative Example 18), during the subsequent 65°C incubation and stirring and the addition of cysteine protective solution, the indole ring may accumulate due to local supersaturation, resulting in a decrease in light absorption efficiency; at the same time, the tryptophan added in advance is consumed before the system under light and heat conditions, losing its function as an endogenous light shielding agent in the final drug solution. (4) Comparative Example 7 (sulfite) is only critically qualified, with a tryptophan retention rate of 86.3%, and the photodegradation products are significantly higher than those in the example. Although sulfite can slightly inhibit photo-oxidation, it decomposes rapidly under light, and the protective effect decays rapidly with the light exposure time. At the same time, the decomposition products will add new impurities. (5) The comparative ratio of excessive photodegradation due to lack of nitrogen deoxygenation and excessive headspace residual oxygen is that oxygen is the core substrate of photooxidation reaction. High residual oxygen will greatly amplify the oxidation rate of amino acids under light. Nitrogen gas sealing and oxygen isolation, along with acetic acid chemical protection, work together to achieve dual stability of photooxidation.
[0161] 6. Long-term stability assessment The present invention also conducted long-term stability studies on the compound amino acid injections of Example 11, Comparative Example 1, and Comparative Example 7. The experimental results are as follows: Table 8. Long-term stability studies of amino acid content in Examples 11, 1 (Comparative Example), and 7. result
[0162]
[0163]
[0164]
[0165] The above experiments show that, at the end of 12 months of long-term storage at room temperature, all indicators in Example 11 remained stable throughout the process, and the drug solution remained colorless and clear. The levels of cystine impurities and total related substances were far superior to those in the two control groups. Both control groups showed significant deterioration, as analyzed below: (1) After long-term storage, Comparative Example 1 (without acetic acid pre-protection and without antioxidants) retained only 81.9% of cysteine, with cystine impurities at 23 μg / ml. The drug solution was pale yellow and showed a tendency to become turbid. Nitrogen gas alone cannot physically block the slow oxidation of thiol groups. The acidic microenvironment without acetic acid continuously shields -S - At room temperature, trace amounts of dissolved oxygen undergo continuous chain oxidation over many years, leading to irreversible accumulation of cystine and an increase in photosensitive impurities that cause discoloration of the drug solution, making it completely unable to meet the 2-year shelf life requirement. (2) Comparative Example 7 (commercially available sulfite formulation) was visually acceptable throughout the process, but after 12 months, the total related substances were 0.66% and cystine was 15 μg / ml, with indicators consistently worse than those of the Example. Sulfites decompose slowly year by year, continuously generating sulfate and sulfide byproducts, which continuously increases the total amount of related substances; moreover, sulfites pose a clear clinical allergy risk, and there are safety hazards for infusion in patients with liver dysfunction and asthma. This invention does not add any exogenous antioxidant excipients and relies on the process to achieve better impurity control and higher clinical safety. (3) The long-term stable core mechanism of Example 11 of the present invention: a special protection strategy is designed for three easily oxidized amino acids, namely cysteine, methionine and tryptophan. Acetic acid pre-dissolves the thiol group at the molecular level, and the natural synergistic antioxidant network is constructed by segmented feeding. The nitrogen gas is sealed throughout the process to eliminate oxidizing substrates. Multiple protections are superimposed to achieve room temperature stability for up to 12 months without antioxidants. This overcomes the industry bottleneck of existing technologies that require the addition of sulfites and acetylcysteine derivatives, and achieves comprehensive technical effects that cannot be achieved by existing technologies.
[0166] The above embodiments are merely illustrative of the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to the preferred embodiments above, those skilled in the art should understand that modifications or equivalent substitutions to the technical solutions of the present invention should not depart from the spirit and scope of the present invention. Those skilled in the art can also make other changes within the spirit of the present invention and use them in the design of the present invention, as long as they do not deviate from the technical effects of the present invention. These changes made according to the spirit of the present invention should all be included within the scope of protection claimed by the present invention.
Claims
1. A method for preparing an antioxidant-free compounded amino acid injection, characterized by, Includes the following steps: S1. Dissolve the prescribed amount of cysteine in an acetic acid solution with a mass-volume percentage of 40-80% prepared under nitrogen protection to prepare a cysteine protective solution with a cysteine concentration of 0.5-2.0 g / L. S2. Add a predetermined amount of water for injection to the mixing tank, and fill the mixing tank with nitrogen until the dissolved oxygen is stable at no more than 0.2 ppm to obtain the basic solvent; S3. Arginine, tyrosine, isoleucine, leucine, lysine acetate, phenylalanine, threonine, valine, alanine, aspartic acid, proline, serine, histidine, and glycine are added to the base solvent and stirred continuously until all solid materials are completely clear and dissolved to obtain the initial drug solution. S4. Add methionine to the initial drug solution, stir to dissolve, then add tryptophan and continue stirring to obtain the first mixed drug solution. S5. The cysteine acetic acid protective solution is added dropwise to the first mixed drug solution at a rate of 1L / min to 2.5L / min, while stirring during the addition process. The mixture is then mixed to obtain the second mixed drug solution, and the pH value is adjusted to 6.6 to 7.6 using glacial acetic acid solution. S6. Add water for injection to dilute the second mixed drug solution to a final volume. Under nitrogen protection, reflux and circulate the drug solution for 20 minutes to obtain the final drug solution. It also includes a step of multi-stage filtration of the final drug solution: S7. Primary filtration is performed using composite PES filter elements of 0.65μm and 0.45μm. S8. Secondary filtration is performed using a 0.22μm PES sterilization filter cartridge; S9. Three-stage filtration is performed using a 0.22μm PES terminal sterilization filter cartridge to obtain the filtered drug solution. The pressure of the multi-stage filtration is maintained at 0.10 MPa to 0.30 MPa; S10. Filling: Fill the filtered medicine solution into glass infusion bottles, and accurately control the headspace residual oxygen content in the bottle to ≤1.0% after filling; S11. Sterilization: Sterilization temperature 121.0℃, sterilization time 12min, after sterilization, cooling in stages to obtain compound amino acid injection; Step S1 is completed at any stage prior to step S5.
2. The preparation method of the antioxidant-free compounded amino acid injection according to claim 1, characterized by, In step S1, the acetic acid solution has a mass-volume percentage of 60%.
3. The method for preparing the antioxidant-free compound amino acid injection according to claim 1, characterized in that, During the secondary and tertiary filtration processes, the temperature of the final drug solution is maintained between 20°C and 40°C.
4. The method for preparing the antioxidant-free compound amino acid injection according to claim 1, characterized in that, In steps S2, S3, S4, and S5, the water temperature for injection is controlled to be constant at 65±5℃.
5. The application of a compound amino acid injection obtained by any one of claims 1 to 4 in the preparation of amino acid-based intravenous nutrition drugs.
6. The compound amino acid injection obtained by the production method according to any one of claims 1 to 4, characterized by, Including arginine, tyrosine, isoleucine, leucine, lysine acetate, phenylalanine, threonine, valine, alanine, aspartic acid, proline, serine, histidine, glycine, methionine, tryptophan, cysteine, and water for injection.
7. The amino acid injection of claim 6, wherein The concentrations of the following amino acids were as follows: arginine (13.93 g / L–16.91 g / L); tyrosine (0.36 g / L–0.44 g / L); isoleucine (8.28 g / L–10.12 g / L); leucine (8.51 g / L–10.40 g / L); lysine acetate (3.56 g / L–4.35 g / L); phenylalanine (0.27 g / L–0.33 g / L); threonine (1.93 g / L–2.35 g / L); and valine (8.01 g / L–9.79 g / L). g / L; alanine concentration 7.56 g / L~9.24 g / L; aspartic acid concentration 0.18 g / L~0.22 g / L; proline concentration 4.77 g / L~5.83 g / L; serine concentration 2.34 g / L~2.86 g / L; histidine concentration 2.79 g / L~3.41 g / L; glycine concentration 4.86 g / L~5.94 g / L; methionine concentration 0.40 g / L~0.48 g / L; tryptophan concentration 0.63 g / L~0.77 g / L; The cysteine concentration was 0.23 g / L to 0.28 g / L.
Citation Information
Patent Citations
Compound amino acid composition and preparation method thereof
CN112999148A
Compound amino acid injection as well as application and preparation method thereof
CN115317590A
Preparation method of compound amino acid composition without antioxidant
CN116251058B
Compound amino acid injection composition as well as preparation method and application thereof
CN121177442A
Preparation method and application of compound amino acid injection
CN121606533A
